Dimethyl sulfoxide: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
m (Protected "Dimethyl sulfoxide": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(6 intermediate revisions by one other user not shown)
Line 3: Line 3:
|genericName=Dimethyl sulfoxide
|genericName=Dimethyl sulfoxide
|aOrAn=an
|aOrAn=an
|drugClass=anti inflammatory
|drugClass=[[anti inflammatory]]
|indicationType=treatment
|indicationType=treatment
|indication=symptomatic relief of patients with interstitial cystitis
|indication=symptomatic relief of patients with [[interstitial cystitis]]
|adverseReactions=garlic breath, garlic taste , chemical cystitis
|adverseReactions=[[garlic breath]], [[garlic taste]], chemical [[cystitis]]
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
Line 15: Line 15:


<!--FDA-Labeled Indications and Dosage (Adult)-->
<!--FDA-Labeled Indications and Dosage (Adult)-->
|fdaLIADAdult=* RIMSO-50® (dimethyl sulfoxide) is indicated for the symptomatic relief of patients with interstitial cystitis. RIMSO-50® has not been approved as being safe and effective for any other indication.  
|fdaLIADAdult=* Dimethyl sulfoxide is indicated for the symptomatic relief of patients with [[interstitial cystitis]]. Dimethyl sulfoxide has not been approved as being safe and effective for any other indication.  
* There is no clinical evidence of effectiveness of dimethyl sulfoxide in the treatment of bacterial infections of the urinary tract.
* There is no clinical evidence of effectiveness of dimethyl sulfoxide in the treatment of [[bacterial infections]] of the urinary tract.
* Instillation of 50 mL of RIMSO-50® (dimethyl sulfoxide) directly into the bladder may be accomplished by catheter or asepto syringe and allow to remain for 15 minutes. Application of an analgesic lubricant gel such as lidocaine jelly to the urethra is suggested prior to insertion of the catheter to avoid spasm. The medication is expelled by spontaneous voiding. It is recommended that the treatment be repeated every two weeks until maximum symptomatic relief is obtained. Thereafter, time intervals between therapy may be increased appropriately.
* Instillation of 50 mL of dimethyl sulfoxide directly into the bladder may be accomplished by catheter or aseptic syringe and allow to remain for 15 minutes. Application of an analgesic lubricant gel such as [[lidocaine]] jelly to the [[urethra]] is suggested prior to insertion of the catheter to avoid spasm. The medication is expelled by spontaneous voiding. It is recommended that the treatment be repeated every two weeks until maximum symptomatic relief is obtained. Thereafter, time intervals between therapy may be increased appropriately.
* Administration of oral analgesic medication or suppositories containing belladonna and opium prior to the instillation of RIMSO-50® can reduce bladder spasm.
* Administration of oral analgesic medication or suppositories containing belladonna and opium prior to the instillation of dimethyl sulfoxide can reduce bladder spasm.
* In patients with severe interstitial cystitis with very sensitive bladders, the initial treatment, and possibly the second and third (depending on patient response) should be done under anesthesia. (Saddle block has been suggested).
* In patients with severe interstitial cystitis with very sensitive bladders, the initial treatment, and possibly the second and third (depending on patient response) should be done under [[anesthesia]]. (Saddle block has been suggested).
* Instillation of 50 mL of RIMSO-50® (dimethyl sulfoxide) directly into the bladder may be accomplished by catheter or asepto syringe and allow to remain for 15 minutes. Application of an analgesic lubricant gel such as lidocaine jelly to the urethra is suggested prior to insertion of the catheter to avoid spasm. The medication is expelled by spontaneous voiding. It is recommended that the treatment be repeated every two weeks until maximum symptomatic relief is obtained. Thereafter, time intervals between therapy may be increased appropriately.
* Instillation of 50 mL of dimethyl sulfoxide directly into the bladder may be accomplished by catheter or asepto syringe and allow to remain for 15 minutes. Application of an analgesic lubricant gel such as lidocaine jelly to the [[urethra]] is suggested prior to insertion of the catheter to avoid spasm. The medication is expelled by spontaneous voiding. It is recommended that the treatment be repeated every two weeks until maximum symptomatic relief is obtained. Thereafter, time intervals between therapy may be increased appropriately.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Dimethyl sulfoxide in adult patients.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of dimethyl sulfoxide in adult patients.
|offLabelAdultNoGuideSupport=* Injection site extravasation
|offLabelAdultNoGuideSupport=* Injection site extravasation
|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
Line 31: Line 31:
<!--Contraindications-->
<!--Contraindications-->
|contraindications=* None known.
|contraindications=* None known.
|warnings=* Dimethyl sulfoxide can initiate the liberation of histamine and there has been occasional hypersensitivity reaction with topical administration of dimethyl sulfoxide. This hypersensitivity has been reported in one patients receiving intravesical RIMSO-50®. The physician should be cognizant of this possibility in prescribing RIMSO-50®. If anaphylactoid symptoms develop, appropriate therapy should be instituted.
|warnings=* Dimethyl sulfoxide can initiate the liberation of histamine and there has been occasional hypersensitivity reaction with topical administration of dimethyl sulfoxide. This hypersensitivity has been reported in one patients receiving intravesical dimethyl sulfoxide. The physician should be cognizant of this possibility in prescribing . If anaphylactoid symptoms develop, appropriate therapy should be instituted.
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=* Dimethyl sulfoxide can initiate the liberation of histamine and there has been occasional hypersensitivity reaction with topical administration of dimethyl sulfoxide.
|postmarketing=* Dimethyl sulfoxide can initiate the liberation of histamine and there has been occasional hypersensitivity reaction with topical administration of dimethyl sulfoxide.
* This hypersensitivity has been reported in one patients receiving intravesical RIMSO-50®. The physician should be cognizant of this possibility in prescribing RIMSO-50®. If anaphylactoid symptoms develop, appropriate therapy should be instituted.
* This hypersensitivity has been reported in one patients receiving intravesical RIMSO-50®. The physician should be cognizant of this possibility in prescribing dimethyl sulfoxide. If anaphylactoid symptoms develop, appropriate therapy should be instituted.
|drugInteractions=* Drug
|drugInteractions=
:* Description
 
<!--Use in Specific Populations-->
<!--Use in Specific Populations-->
|FDAPregCat=C
|FDAPregCat=C
Line 56: Line 54:


<!--Administration and Monitoring-->
<!--Administration and Monitoring-->
|administration=* Intravesical instillation
|administration=* [[Intravesical instillation]]
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.


Line 65: Line 63:


<!--Overdosage-->
<!--Overdosage-->
|overdose=* The oral LD50 of dimethyl sulfoxide in the dog is greater than 10 gm/kg. It is improbable that this dosage level could be obtained with intravesical instillation of RIMSO-50® in the patient.
|overdose=* The oral LD50 of dimethyl sulfoxide in the dog is greater than 10 gm/kg. It is improbable that this dosage level could be obtained with intravesical instillation of dimethyl sulfoxide in the patient.
* In case of accidental oral ingestion, specific measures should be taken to induce emesis. Additional measures which may be considered are gastric lavage, activated charcoal and force diuresis.
* In case of accidental oral ingestion, specific measures should be taken to induce emesis. Additional measures which may be considered are gastric lavage, activated charcoal and force diuresis.
|drugBox={{Chembox2  
|drugBox={{Chembox2  
Line 123: Line 121:


NOT FOR INTRAMUSCULAR OR INTRAVENOUS INJECTION.
NOT FOR INTRAMUSCULAR OR INTRAVENOUS INJECTION.
* The active component of RIMSO-50® is dimethyl sulfoxide which has the empirical formula C2H6OS, and is structurally represented as:
* The active component of the compound is dimethyl sulfoxide which has the empirical formula C2H6OS, and is structurally represented as:
: [[File:Dimethylsulfoxide.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
: [[File:Dimethylsulfoxide.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
* Dimethyl sulfoxide is a clear, colorless and essentially odorless liquid which is miscible with water and most organic solvents. Other physical characteristics include: molecular weight 78.13, melting point 18.3° C, and a specific gravity of 1.096.
* Dimethyl sulfoxide is a clear, colorless and essentially odorless liquid which is miscible with water and most organic solvents. Other physical characteristics include: molecular weight 78.13, melting point 18.3° C, and a specific gravity of 1.096.
Line 139: Line 137:


<!--How Supplied-->
<!--How Supplied-->
|howSupplied=*Vials contain 50 mL of sterile and non-pyrogenic RIMSO-50® (50% w/w dimethyl sulfoxide aqueous solution).
|howSupplied=*Vials contain 50 mL of sterile and non-pyrogenic dimethyl sulfoxide (50% w/w dimethyl sulfoxide aqueous solution).
* Dimethyl sulfoxide is clear and colorless.
* Dimethyl sulfoxide is clear and colorless.
* NDC 67457-177-50
* NDC 67457-177-50
Line 145: Line 143:
|storage=* Store at 20° to 25°C (68° to 77°F)
|storage=* Store at 20° to 25°C (68° to 77°F)
|packLabel=<!--Patient Counseling Information-->
|packLabel=<!--Patient Counseling Information-->
|fdaPatientInfo=* RIMSO-50® is a sterile solution of 50% dimethyl sulfoxide (DMSO) and 50% water that has been approved by the U.S. Food and Drug Administration for use in the symptomatic relief of patients with interstitial cystitis.
|fdaPatientInfo=* Dimethyl sulfoxide is a sterile solution of 50% dimethyl sulfoxide (DMSO) and 50% water that has been approved by the U.S. Food and Drug Administration for use in the symptomatic relief of patients with interstitial cystitis.
* RIMSO-50® will be instilled in the bladder on an inpatient or out-patient basis, which will be determined by your physician.
* Dimethyl sulfoxide will be instilled in the bladder on an inpatient or out-patient basis, which will be determined by your physician.
* Some data indicate that dimethyl sulfoxide could change the effectiveness of medication(s) that you may be presently receiving. Be sure to mention the name and dosage of all medicines you are taking to your physician before a RIMSO-50® instillation.
* Some data indicate that dimethyl sulfoxide could change the effectiveness of medication(s) that you may be presently receiving. Be sure to mention the name and dosage of all medicines you are taking to your physician before a dimethyl sulfoxide instillation.
* A garlic-like taste may be noted by the patient within a few minutes after instillation of RIMSO-50® (dimethyl sulfoxide). This taste may last several hours. An odor on the breath and skin may be present and remain for up to 72 hours.
* A garlic-like taste may be noted by the patient within a few minutes after instillation of dimethyl sulfoxide. This taste may last several hours. An odor on the breath and skin may be present and remain for up to 72 hours.
* Some patients may experience discomfort on administration of the drug. Usually this becomes less prominent with repeated administration.
* Some patients may experience discomfort on administration of the drug. Usually this becomes less prominent with repeated administration.
* If you are pregnant or nursing, ask your physician about the advisability of using RIMSO-50®.
* If you are pregnant or nursing, ask your physician about the advisability of using RIMSO-50®.
Line 158: Line 156:


<!--Look-Alike Drug Names-->
<!--Look-Alike Drug Names-->
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
<!--Drug Shortage Status-->
|drugShortage=
|drugShortage=
}}
}}
Line 182: Line 177:


[[Category:Drug]]
[[Category:Drug]]
[[Category:Solvents]]
[[Category:Sulfoxides]]

Latest revision as of 20:01, 18 August 2015

Dimethyl sulfoxide
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Dimethyl sulfoxide is an anti inflammatory that is FDA approved for the treatment of symptomatic relief of patients with interstitial cystitis. Common adverse reactions include garlic breath, garlic taste, chemical cystitis.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • Dimethyl sulfoxide is indicated for the symptomatic relief of patients with interstitial cystitis. Dimethyl sulfoxide has not been approved as being safe and effective for any other indication.
  • There is no clinical evidence of effectiveness of dimethyl sulfoxide in the treatment of bacterial infections of the urinary tract.
  • Instillation of 50 mL of dimethyl sulfoxide directly into the bladder may be accomplished by catheter or aseptic syringe and allow to remain for 15 minutes. Application of an analgesic lubricant gel such as lidocaine jelly to the urethra is suggested prior to insertion of the catheter to avoid spasm. The medication is expelled by spontaneous voiding. It is recommended that the treatment be repeated every two weeks until maximum symptomatic relief is obtained. Thereafter, time intervals between therapy may be increased appropriately.
  • Administration of oral analgesic medication or suppositories containing belladonna and opium prior to the instillation of dimethyl sulfoxide can reduce bladder spasm.
  • In patients with severe interstitial cystitis with very sensitive bladders, the initial treatment, and possibly the second and third (depending on patient response) should be done under anesthesia. (Saddle block has been suggested).
  • Instillation of 50 mL of dimethyl sulfoxide directly into the bladder may be accomplished by catheter or asepto syringe and allow to remain for 15 minutes. Application of an analgesic lubricant gel such as lidocaine jelly to the urethra is suggested prior to insertion of the catheter to avoid spasm. The medication is expelled by spontaneous voiding. It is recommended that the treatment be repeated every two weeks until maximum symptomatic relief is obtained. Thereafter, time intervals between therapy may be increased appropriately.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of dimethyl sulfoxide in adult patients.

Non–Guideline-Supported Use

  • Injection site extravasation

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Dimethyl sulfoxide in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Dimethyl sulfoxide in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dimethyl sulfoxide in pediatric patients.

Contraindications

  • None known.

Warnings

  • Dimethyl sulfoxide can initiate the liberation of histamine and there has been occasional hypersensitivity reaction with topical administration of dimethyl sulfoxide. This hypersensitivity has been reported in one patients receiving intravesical dimethyl sulfoxide. The physician should be cognizant of this possibility in prescribing . If anaphylactoid symptoms develop, appropriate therapy should be instituted.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Dimethyl sulfoxide in the drug label.

Postmarketing Experience

  • Dimethyl sulfoxide can initiate the liberation of histamine and there has been occasional hypersensitivity reaction with topical administration of dimethyl sulfoxide.
  • This hypersensitivity has been reported in one patients receiving intravesical RIMSO-50®. The physician should be cognizant of this possibility in prescribing dimethyl sulfoxide. If anaphylactoid symptoms develop, appropriate therapy should be instituted.

Drug Interactions

There is limited information regarding Dimethyl sulfoxide Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): C

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Dimethyl sulfoxide in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Dimethyl sulfoxide during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Dimethyl sulfoxide with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Dimethyl sulfoxide with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Dimethyl sulfoxide with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Dimethyl sulfoxide with respect to specific gender populations.

Race

There is no FDA guidance on the use of Dimethyl sulfoxide with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Dimethyl sulfoxide in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Dimethyl sulfoxide in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Dimethyl sulfoxide in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Dimethyl sulfoxide in patients who are immunocompromised.

Administration and Monitoring

Administration

Monitoring

There is limited information regarding Monitoring of Dimethyl sulfoxide in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Dimethyl sulfoxide in the drug label.

Overdosage

  • The oral LD50 of dimethyl sulfoxide in the dog is greater than 10 gm/kg. It is improbable that this dosage level could be obtained with intravesical instillation of dimethyl sulfoxide in the patient.
  • In case of accidental oral ingestion, specific measures should be taken to induce emesis. Additional measures which may be considered are gastric lavage, activated charcoal and force diuresis.

Pharmacology

Template:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox E numberTemplate:Chembox RTECSTemplate:Chembox AppearanceTemplate:Chembox DensityTemplate:Chembox MeltingPtTemplate:Chembox BoilingPtTemplate:Chembox SolubilityInWaterTemplate:Chembox RefractIndexTemplate:Chembox ViscosityTemplate:Chembox StructureTemplate:Chembox MainHazardsTemplate:Chembox RPhrasesTemplate:Chembox SPhrasesTemplate:Chembox NFPATemplate:Chembox FlashPtTemplate:Chembox Supplement
Template:Chembox header2 | Dimethyl sulfoxide
Identifiers
3D model (JSmol)
ECHA InfoCard Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
Properties
C2H6OS
Molar mass 78.13 g/mol
Hazards
Related compounds
Template:Chembox header2 | Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references

Mechanism of Action

There is limited information regarding Dimethyl sulfoxide Mechanism of Action in the drug label.

Structure

RIMSO-50®(dimethyl sulfoxide) (DMSO) 50% w/w Aqueous Solution for intravesical instillation.

Each mL contains 0.54 gm dimethyl sulfoxide STERILE AND NON-PYROGENIC.

Intravesical instillation for the treatment of interstitial cystitis.

NOT FOR INTRAMUSCULAR OR INTRAVENOUS INJECTION.

  • The active component of the compound is dimethyl sulfoxide which has the empirical formula C2H6OS, and is structurally represented as:
This image is provided by the National Library of Medicine.
  • Dimethyl sulfoxide is a clear, colorless and essentially odorless liquid which is miscible with water and most organic solvents. Other physical characteristics include: molecular weight 78.13, melting point 18.3° C, and a specific gravity of 1.096.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Dimethyl sulfoxide in the drug label.

Pharmacokinetics

  • Dimethyl sulfoxide is metabolised in man by oxidation to dimethyl sulfone or by reduction to dimethyl sulfide. Dimethyl sulfoxide and dimethyl sulfone are excreted in the urine and feces.
  • Dimethyl sulfide is eliminated through the breath and skin and is responsible for the characteristic odor from patients on dimethyl sulfoxide medication. Dimethyl sulfone can persist in serum for longer than two weeks after a single intravesical instillation. No residual accumulation of dimethyl sulfoxide has occurred in man or lower animals who have received treatment for protracted periods of time. Following topical application, dimethyl sulfoxide is absorbed and generally distributed in the tissues and body fluids.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Dimethyl sulfoxide in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Dimethyl sulfoxide in the drug label.

How Supplied

  • Vials contain 50 mL of sterile and non-pyrogenic dimethyl sulfoxide (50% w/w dimethyl sulfoxide aqueous solution).
  • Dimethyl sulfoxide is clear and colorless.
  • NDC 67457-177-50
  • Carton containing a 50 mL vial

Storage

  • Store at 20° to 25°C (68° to 77°F)

Images

Drug Images

{{#ask: Page Name::Dimethyl sulfoxide |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Dimethyl sulfoxide |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

  • Dimethyl sulfoxide is a sterile solution of 50% dimethyl sulfoxide (DMSO) and 50% water that has been approved by the U.S. Food and Drug Administration for use in the symptomatic relief of patients with interstitial cystitis.
  • Dimethyl sulfoxide will be instilled in the bladder on an inpatient or out-patient basis, which will be determined by your physician.
  • Some data indicate that dimethyl sulfoxide could change the effectiveness of medication(s) that you may be presently receiving. Be sure to mention the name and dosage of all medicines you are taking to your physician before a dimethyl sulfoxide instillation.
  • A garlic-like taste may be noted by the patient within a few minutes after instillation of dimethyl sulfoxide. This taste may last several hours. An odor on the breath and skin may be present and remain for up to 72 hours.
  • Some patients may experience discomfort on administration of the drug. Usually this becomes less prominent with repeated administration.
  • If you are pregnant or nursing, ask your physician about the advisability of using RIMSO-50®.
  • Some eye changes have been observed in animals treated with DMSO in large doses for prolonged periods. Therefore your doctor may want you to have eye evaluations, including slit lamp examinations prior to and periodically during treatment.

Precautions with Alcohol

  • Alcohol-Dimethyl sulfoxide interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

There is limited information regarding Dimethyl sulfoxide Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ "RIMSO-50- dimethyl sulfoxide irrigant".

{{#subobject: 

 |Label Page=Dimethyl sulfoxide
 |Label Name=Dimethyl sulfoxide.jpg

}}

{{#subobject: 

 |Label Page=Dimethyl sulfoxide
 |Label Name=DailyMed - RIMSO-50- dimethyl sulfoxide irrigant   (1).png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Dimethyl_sulfoxide&oldid=1135190"